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ABSTRACT: Adrenomedullin (ADM) and proadrenomedullin N-terminal 20
peptide (PAMP) are two peptides with vasodilative, bronchodilative, and
angiogenic properties, originating from a common precursor, proADM.
Previous studies proposed that the atypical chemokine receptor ACKR3
might act as a low-affinity scavenger for ADM, regulating its availability for its
cognate receptor calcitonin receptor-like receptor (CLR) in complex with a
receptor activity modifying protein (RAMP). In this study, we compared the
activation of ACKR3 by ADM and PAMP, as well as other related members of
the calcitonin gene-related peptide (CGRP) family. Irrespective of the
presence of RAMPs, ADM was the only member of the CGRP family to
show moderate activity toward ACKR3. Remarkably, PAMP, and especially
further processed PAMP-12, had a stronger potency toward ACKR3 than
ADM. Importantly, PAMP-12 induced β-arrestin recruitment and was
efficiently internalized by ACKR3 without inducing G protein or ERK
signaling in vitro. Our results further extend the panel of endogenous ACKR3 ligands and broaden ACKR3 functions to a regulator
of PAMP-12 availability for its primary receptor Mas-related G-protein-coupled receptor member X2 (MrgX2).
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Atypical chemokine receptors (ACKRs) are vital regulatorsof the spatiotemporal distribution of chemokines. ACKRs
mediate chemokine internalization, degradation, sequestration,
or transcytosis without inducing classical G-protein-mediated
signaling.1 ACKR3, formerly named CXCR7, is expressed
ubiquitously but is most abundantly present in different brain
regions, adrenal glands, lymphatic and blood vasculature, heart,
and various subsets of immune cells.2,3 ACKR3 is a selective
scavenger for two endogenous chemokines, CXCL12 and
CXCL11, which are also the ligands of CXCR4 and CXCR3,
respectively, and for the human herpesvirus 8 (HHV-8)-
encoded chemokine vCCL2, as well as the pseudochemokine
MIF.4−6 Recently, it has also been shown that ACKR3 is a
high-affinity scavenger for a broad spectrum of opioid peptides
and modulates their availability for classical opioid receptors.7,8
ACKR3 regulates embryogenesis, hematopoiesis, neuronal
migration, angiogenesis, and cardiac development.4,7,9 Genetic
knockout of Ackr3 in mice is associated with cardiomyocyte
hyperplasia and disrupted lymphangiogenesis, usually leading
to perinatal death due to cardiac valve and ventricular septal
defects.10,11 However, these defects do not correlate with the
CXCL12-CXCR4 signaling axis, suggesting that ACKR3
interaction with ligands other than CXCL12 may be
responsible for this phenotype. Interestingly, recent studies
proposed that besides its chemokine and opioid ligands,
ACKR3 acts as a molecular rheostat for the proangiogenic
peptide adrenomedullin (ADM).12,13 Indeed, Ackr3 knockout
recapitulates the Adm overexpression phenotype, and genetic
reduction of Adm expression counterbalances lymphatic and
cardiac abnormalities observed in Ackr3 knockout mice.12
Adrenomedullin is a 52 amino acid (AA) peptide, acting as a
vital paracrine factor to promote cardiac development,
vasodilation, and formation of blood and lymph vessels.14,15
Due to its proangiogenic properties, ADM is also a key player
in tumor growth.16 ADM belongs to calcitonin/calcitonin
gene-related peptide (CGRP) family that also includes α-
CGRP and β-CGRP, intermedin/adrenomedullin 2 (IMD/
ADM2), amylin (AMY), and calcitonin (CT).17 ADM binds
and activates the G-protein-coupled receptor (GPCR)
calcitonin receptor-like receptor (CLR), which can only be
exported to the cell surface upon heterodimerization with one
of the three accessory membrane proteins called receptor
activity modifying proteins (RAMPs).18−20 RAMP interactions
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also define the pharmacological profile of CLR. While a
complex with either RAMP2 or RAMP3 generates a selective
ADM receptor, dimerization with RAMP1 creates a receptor
for CGRP with only low affinity for ADM.17
Adrenomedullin is generated through the proteolysis of a
precursor molecule called proadrenomedullin (proADM),
which also gives rise to the proadrenomedullin N-terminal
20 peptide (PAMP) (Figure 1A).21,22 PAMP is a 20 AA
peptide involved in similar processes as ADM, but it differs in
size and sequence and has no activity toward the ADM
receptor complex CLR/RAMPs. Instead, the Mas-related G-
protein-coupled receptor member X2 (MrgX2 or MRGPRX2)
was proposed as the receptor for PAMP as well as for its
endogenously processed form, PAMP-12, consisting of AAs 9−
20.23,24 It is still unknown whether the observed physiological
effects of PAMP rely exclusively on MrgX2 or on additional
receptors. Although the vast majority of studies focus on ADM
rather than on PAMP functions, both peptides are often found
in the same regions and exert similar effects,25,26 suggesting
that they may act in parallel. However, the roles and the
receptors of PAMP are largely under-investigated.
Although important biological and genetic links have been
established between ADM expression and ACKR3,10,12 the
exact regulatory role of ACKR3 in ADM signaling, the
pharmacological properties of ADM toward ACKR3 as well as
the possible impact of ACKR3 on other proADM-derived
peptides and ligands of the CGRP family have not been
comprehensively assessed.13,27
In this study, we demonstrate that ADM is the only member
of the CGRP family that activates ACKR3, with moderate
micromolar-range activity. Remarkably, we found that PAMP,
the second active peptide released during proADM maturation,
has an activity toward ACKR3 that is comparable to ADM. Its
truncated endogenous analog PAMP-12 especially shows a
greater potency toward ACKR3 than ADM, which is
comparable to the high-nanomolar range activity toward its
previously identified receptor MrgX2. ACKR3 induces β-
arrestin recruitment and drives PAMP-12 internalization, but
in contrast to MrgX2, it does not induce classical G protein
Figure 1. ADM is the only CGRP-family member with limited ACKR3 activity not influenced by RAMPs. (A) Schematic overview of preproADM
processing into at least two active peptides (PAMP and ADM) and adrenotensin (ADT), whose bioactivity has to be confirmed. Amino acid (AA)
motifs recognized by pro-protein convertases potentially involved during pro-ADM maturation are indicated. MR-proADM: midregional
proadrenomedullin, SP: signal peptide. (B−D) Efficacy and potency of different CGRP family members in inducing β-arrestin recruitment toward
ACKR3 (B and C) or CLR (D) in HEK cells in the absence of regulatory proteins (B), or in the presence of one of the three RAMPs or CD8 used
as negative control protein (C and D) using NanoBiT technology. Results are expressed as percentage of full agonist response and represent the
mean ± SEM of three independent experiments (n = 3).
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signaling or ERK phosphorylation. Our data suggest that the
ADM-encoded PAMP-12 peptide is an additional endogenous
ligand of ACKR3 and cast light on the potential role of PAMP-
12, along with ADM, on the phenotypes observed in Adm
knockout animals or overexpression experiments.
■ RESULTS AND DISCUSSION
ADM Is the Only CGRP Family Member Showing
Activity toward ACKR3. In order to characterize the activity
and pharmacology of ADM toward ACKR3, we first measured
its ability to induce β-arrestin-2 recruitment to ACKR3 using a
nanoluciferase complementation-based assay (NanoBiT). We
additionally included other structurally and functionally related
peptides of the CGRP family, namely, α-CGRP, intermedin
(IMD), amylin (AMY), and calcitonin (CT), to investigate the
selectivity of ACKR3. Among these peptides, only ADM
showed moderate activity toward ACKR3, triggering at the
highest concentration tested (9 μM) about 50% of the
maximum response observed with the full agonist CXCL12
(Figure 1B). No activity was detected with any of the other
members of the CGRP family. However, although ACKR3 can
heterodimerize with all three RAMP isoforms (Supplementary
Figure 1), coexpression of ACKR3 with RAMPs did not
improve its responsiveness to ADM, as already suggested in a
recent study,13 or to any other CGRP family ligands (Figure
1C and Supplementary Table 1). In contrast, CLR activation
Figure 2. PAMP peptides have comparable activity toward ACKR3 and MrgX2 and no activity toward any other chemokine receptor. (A)
Sequences of ADM and the three PAMP variants tested: full-length PAMP, comprising AAs 1−20; PAMP-12, comprising AAs 9−20; and
PAMP(12−20), comprising the last 9 AAs of PAMP. For ADM, cysteine residues involved in a disulfide bridge forming a 4-residue intrapeptide
arch are depicted in red. (B−C) Comparison of potency and efficacy of different active PAMP variants, ADM, ADT, and substance P in inducing β-
arrestin-2 toward ACKR3 (B) or MrgX2 (C) in HEK cells, normalized to percent activity of their respective full agonists. (D) Binding competition
of CGRP, ADM, and PAMP variants (9 μM) with AlexaFluor647-labeled CXCL12 (5 nM) on HEK-ACKR3 cells determined by flow cytometry.
(E) Agonist activity of ADM and different PAMP variants (3 μM) toward all chemokine receptors, as well as the MrgX2 and GPR182 monitored in
a β-arrestin-2 recruitment assay. Results are expressed as fold change over vehicle. For each receptor, an agonist chemokine (100 nM) listed in the
IUPHAR repository of chemokine receptor ligands was used as the positive control. Results from B−E are represented as mean ± SEM of three
independent experiments. **, p < 0.01 by one-way ANOVA with Bonferroni multiple comparison test.
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was only observed upon coexpression of one of the three
RAMP isoforms, as previously described17,18 (Figure 1D and
Supplementary Table 1).
These results confirm that ADM is a weak agonist of
ACKR3 and that its activity and pharmacology are not
influenced by the presence of RAMPs.13 However, the
apparent 300-fold lower ADM activity toward ACKR3
compared to CLR/RAMP2 or CLR/RAMP3 may question
the physiological relevance of ACKR3 as an ADM receptor and
suggests that the regulatory role of ACKR3 in the ADM
signaling axis is either indirect, occurs in a particular
microenvironment, or requires additional, so far unknown,
accessory proteins.28
proADM-Derived PAMP-12 Has a Stronger Potency
toward ACKR3 than Mature ADM. Considering the strong
biological link between ACKR3 and ADM, we wondered
whether ACKR3 might be activated by other peptides
originating from the proADM precursor, namely, proadreno-
medullin N-terminal 20 peptide (PAMP), and adrenotensin
(ADT), a sparsely characterized peptide suggested to exert
angiogenic activity on its own29 (Figure 1A). Surprisingly,
while no activity of ADT could be detected, PAMP induced
slightly lower β-arrestin-2 recruitment toward ACKR3 (EC50 >
10 μM) than did mature ADM (EC50 ≈ 5−10 μM) (Figure
2A,B). Examining further processed forms of PAMP, we found
that PAMP-12, consisting of AAs 9−20 (FRKKWNKWALSR-
NH2) (Figure 2A), showed a much greater potency (EC50 =
839 nM) toward ACKR3 compared to PAMP and ADM and
acted as a full ACKR3 agonist for β-arrestin-2 recruitment
(Figure 2B). PAMP-12 is often considered as the main active
form of PAMP, since it shows stronger in vivo effects. In our
assay it activated MrgX2 with higher potency (EC50 = 785
nM) than did the full-length PAMP (EC50 = 6.2 μM) (Figure
2C and Supplementary Table 1).23,24,30 PAMP(12−20),
Figure 3. SAR analysis of PAMP-12 variants on ACKR3 and MrgX2. (A) Comparison of the impact of substitutions or truncations on the agonist
activity of PAMP-12 toward ACKR3 and MrgX2. The agonist activity of each variant was evaluated in a β-arrestin-2 recruitment assay in HEK cells
and expressed in a heat map as fold change in EC50 values with respect to wild-type PAMP-12. Four variants of PAMP were also included:
PAMP(1−17), PAMP(16−20), PAMP(13−20), and PAMP(4−20). (B−D) Comparison of potency and efficacy of PAMP-12 (B) and its variants
bearing mutations F1Y or K7R in inducing β-arrestin-2 recruitment to ACKR3 (C) and MrgX2 (D) in HEK cells. Results represent the mean (A)
or mean ± SEM (B−D) of three independent experiments (n = 3). The corresponding pEC50 values are available in Supplementary Table 2.
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Figure 4. ACKR3 internalizes PAMP-12 without inducing G protein or ERK-signaling. (A, B) Comparison of miniGi and miniGq recruitment to
ACKR3 (A) and MrgX2 (B) in response to ADM, substance P, and PAMP variants monitored in HEK cells using NanoBiT technology. (C)
Kinetic analysis of ERK1/2 phosphorylation in HEK cells transfected with ACKR3- or MrgX2-encoding plasmids treated with vehicle or PAMP-12
(3 μM). EGF (100 nM) was used as positive control. (D) Activation of ERK (SRE) and Ca2+ (NFAT) signaling cascades in HEK cells expressing
ACKR3 or MrgX2 in response to CXCL12 (300 nM), ADM, substance P, or PAMP variants (3 μM) or positive control (30 nM PMA, 10% FBS
for SRE; 30 nM PMA, 1 μM ionomycin, 10% FBS for NFAT). (E) ACKR3 delivery to endosomes induced by peptides (3 μM) and chemokines
(300 nM) monitored in HEK cells by NanoBRET using nanoluciferase-tagged β-arrestin-2 and mNeonGreen-tagged FYVE domain of endofin,
which binds phosphatidylinositol 3-phosphate (PI3P) in early endosomes. Results are expressed in miliBRET units (mBU). (F−I) Uptake of
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consisting of AAs 12−20 (KWNKWALSR-NH2), had a
reduced potency (EC50 > 10 μM) toward ACKR3, comparable
to that of full-length PAMP, indicating that the determinants
for PAMP-12 activity lie within its N-terminal residues (FRK).
These results were confirmed in a β-arrestin-1 recruitment
assay (Supplementary Figure 2) and in a binding competition
assay, where all identified peptides displaced CXCL12-AF647
from ACKR3, with PAMP-12 being by far the most potent
competitor (Figure 2D). Of note, coexpression with RAMPs
did not modify the activity of PAMP-derived peptides toward
ACKR3, and no activity of PAMP peptides was detected on
CLR or CLR/RAMP complexes (Supplementary Figure 2).
Importantly, while PAMP and PAMP(12−20) had reduced
potency toward ACKR3 compared to that of their classical
receptor MrgX2, PAMP-12 had equivalent potencies toward
both receptors (Figure 2B,C and Supplementary Table 1). In
agreement with the literature, PAMP-12 was also the most
potent PAMP peptide toward MrgX2 in our β-arrestin-2
recruitment assay, although its apparent potency was lower
than that described previously, which may be due to the
different receptor activation readouts used.23 Noteworthy,
ADM did not show any activity toward MrgX2 (Figure 2C)
while substance P, another 11 AA (RPKPQQFFGLM-NH2)
ligand of MrgX2, had no activity toward ACKR3 (Figure 2B),
demonstrating that not all ligands are interchangeable between
ACKR3 and MrgX2.
ACKR3 Is the Only Chemokine Receptor Activated by
proADM-Derived Peptides. The promiscuity of chemokines
for their receptors is remarkable: Many chemokines bind to
several receptors, while a single chemokine receptor can have
multiple ligands. In order to evaluate the selectivity of the
proADM-derived ligands for ACKR3, we screened ADM- and
PAMP-derived peptides (PAMP, PAMP-12, and PAMP(12−
20)) in a β-arrestin-2 recruitment assay toward all known
classical and atypical human chemokine receptors. Our results
show that ADM and PAMP-derived peptides are selective for
ACKR3 and do not activate any of the other 24 chemokine
receptors tested (Figure 2E), while MrgX2 is only activated by
PAMP and its variants but not by mature ADM. Of note, no
activity toward GPR182, the GPCR phylogenetically closest to
ACKR3 and a debated adrenomedullin receptor,31,32 could be
detected upon ligand treatment in this assay. These results
indicate that ACKR3 is the only receptor with dual ADM−
PAMP activation capacity.
PAMP-12 SAR Analysis Pinpoints Different Key
Residues for Activation of ACKR3 Compared to
MrgX2. In order to gain a deeper insight into the activation
mechanism of ACKR3 by this new class of ligands, we
performed a comparative structure−activity relationship (SAR)
analysis using as the basis the most active peptide, PAMP-12,
that shows comparable potencies on the two receptors (Figure
3A,B). In addition to a complete alanine scan, we compared
the impact of different single amino acid substitutions and N-
terminal extensions of PAMP-12, as well as several truncations
of PAMP on the activation of ACKR3 and MrgX2, using β-
arrestin-2 recruitment as readout (Figure 3A and Supple-
mentary Table 2).
This analysis revealed that although a similar trend in
potency shift toward the two receptors was observed for
modifications at multiple positions, including W5, W8, L10, or
R12, important differences could be highlighted. For instance,
a phenylalanine at the first position of the peptide is required
for a strong activity toward ACKR3 (Figure 3A and C). This is
in stark contrast to MrgX2 (Figure 3D), but it is in full
agreement with what we recently found in an adrenorphin SAR
study, where the opposite Y1F mutation led to a 10-fold
enhancement in potency of the peptide toward ACKR38 and
reminiscent of the phenylalanine at position 1 in CXCL11.
Similarly, the SAR analysis revealed that R2 is crucial for
PAMP-12 activity toward ACKR3. Together, these observa-
tions are in line with the previously measured differences in
potency between PAMP-12 and PAMP(12−20) and further
confirm that the determinants for PAMP-12 activity toward
ACKR3 mainly lie within its N-terminal residues. Of all
modifications, only lysine substitutions K3R, K4A, and K7R
improved the potency toward ACKR3, while they were neutral
for MrgX2. This also aligns with the previously reported
adrenorphin SAR study, where the opposite R7K mutation was
detrimental for ACKR3 activation8 and conservation of an
arginine residue at position 7 or 8 within the N terminus of
ACKR3-activating chemokines.27 Overall, these data demon-
strate a high degree of similarity between PAMP, the opioid
core and the N-terminal sequences of the ACKR3 chemokines
probably reflecting a conserved binding mode and ACKR3
binding pocket occupancy. Of note, many mutations had only
a minor impact on ACKR3 and MrgX2, pointing toward a high
propensity for activation of both receptors toward PAMP-12.
However, other truncated PAMP variants including PAMP(1−
17), PAMP(16−20), PAMP(13−20), and PAMP(4−20)
showed no activity toward ACKR3, highlighting some degree
of selectivity of ACKR3 toward this class of ligands. Overall,
this analysis shows that MrgX2 and ACKR3, while both
showing ligand promiscuity, have somewhat different binding
pockets for PAMP peptides.
ACKR3 Mediates PAMP-12 Uptake without Inducing
Signaling Events. The ability of ACKR3 to signal upon
ligand binding is still highly debated and may be cell-type-
dependent. While some studies reported signaling capacity for
ACKR3, especially β-arrestin-dependent ERK phosphoryla-
tion,33,34 others suggested that ACKR3 acts as a non-signaling
scavenger receptor.8,35 In order to assess the ability of ACKR3
to signal in response to proADM-derived peptides, we first
explored the possibility that ACKR3 could couple to G
proteins in response to ADM or PAMP variants by monitoring
Figure 4. continued
fluorescently labeled PAMP-12 (PAMP-12-FAM, 3 μM). (F) Uptake of PAMP-12-FAM by ACKR3-positive or -negative HEK cells pretreated (or
not) with CXCL12 or CXCL10 (200 nM) visualized by imaging flow cytometry. Five representative HEK or HEK-ACKR3 cells are shown. BF:
brightfield. Scale bar: 7 μm. (G) PAMP-12-FAM uptake for conditions described in (F), quantified by mean fluorescence intensity (MFI) and
normalized to signal obtained for nontransfected HEK cells. (H) Percentage of cells with a given number of distinguishable vesicle-like structures
(spots) for conditions determined in (F). (I) PAMP-12-FAM uptake by HEK cells, transiently transfected with equal amounts of ACKR3 or
MrgX2 encoding plasmids or an empty vector (NT) quantified by MFI. For all panels, results represent the mean ± SEM of at least three
independent experiments (n ≥ 3) except for F and H, where one representative experiment of three independent repetitions is shown. *, p < 0.05;
**, p < 0.01; ***, p < 0.001; and ****, p < 0.0001 by one-way ANOVA with Bonferroni (E) or Tuckey’s multiple comparison test (G and I).
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the miniGi and miniGq recruitment to the receptor in a
nanoluciferase complementation-based assay. In contrast to
MrgX2, for which all PAMP variants increased miniGi and
miniGq interactions with the receptor in a concentration-
dependent manner, we did not detect ligand-induced
interactions between ACKR3 and miniGi or miniGq (Figure
4A,B). Furthermore, we did not observe any increase in ERK
phosphorylation upon PAMP-12 treatment, or any activation
of the MAPK/ERK-dependent serum response element (SRE)
and of the calcium-dependent nuclear factor of activated T-cell
response element (NFAT-RE) upon ADM or PAMP
stimulation in ACKR3-transfected cells, in contrast to
MrgX2-transfected cells (Figure 4C,D).
Our data suggest that ADM, PAMP, PAMP(12−20), and
especially PAMP-12 can trigger β-arrestin recruitment to
ACKR3 without inducing classical downstream signaling. In
line with these data, recent studies proposed ACKR3 as a
scavenging receptor for ADM, reducing ADM levels to regulate
its activity.12,13 We therefore wondered whether ACKR3 might
play a similar role for PAMP peptides. To this end, using
nanoluciferase bioluminescence resonance energy transfer
(NanoBRET), we first investigated whether the ACKR3/β-
arrestin complex is internalized and delivered to early
endosomes upon receptor activation by PAMP peptides.36
We observed a robust BRET signal upon treatment of ACKR3-
expressing cells with CXCL12, ADM, and PAMP peptides, but
not with negative controls CXCL10 or substance P, indicative
of a specific delivery of the ligands to endosomes upon binding
to ACKR3 (Figure 4E). Using imaging flow cytometry, we
could also demonstrate that ACKR3 is able to internalize
fluorescently labeled PAMP-12. We observed a clear intra-
cellular accumulation of fluorescently labeled PAMP-12 after
45 min of stimulation of HEK-ACKR3 cells, with a notably
higher number of distinguishable vesicle-like structures and a
higher mean fluorescent intensity compared to those of naiv̈e
HEK cells (Figure 4F−H). Preincubation of HEK-ACKR3
cells with CXCL12, but not with the control chemokine
CXCL10, reduced PAMP-12 accumulation to background
levels, suggesting a specific ACKR3-driven uptake (Figure 4F−
H). Moreover, despite a similar potency of PAMP-12 toward
MrgX2 and ACKR3, MrgX2-positive cells showed significantly
less peptide uptake than ACKR3-positive cells, underscoring
the scavenging capacity of ACKR3 (Figure 4I). In conclusion,
our data suggest that similar to chemokines and endogenous
opioid peptides ACKR3 is able to reduce PAMP-12 availability
by efficiently internalizing the peptide without inducing further
signaling events.
Although PAMP peptides are involved in a variety of
physiological processes like vasodilation, angiogenesis, cell
migration, apoptosis, or degranulation of mast cells, not much
is known about their pharmacological activity or their
physiological regulation. Here, we describe a mechanism of
PAMP-12 regulation via scavenging by ACKR3, which may
restrain peptide availability for its signaling receptor MrgX2.
Interestingly, although MrgX2 and ACKR3 are not closely
related phylogenetically or functionally, both receptors were
recently described to be activated by a variety of small
endogenous opioid peptides such as dynorphins, making
PAMPs their second shared family of ligands.8,37
Regardless of the regulatory role of ACKR3 toward ADM,12
its scavenging capacity for PAMP-12 may be superior and
partly explain why ADM and PAMP, despite their common
precursor, show different and non-equimolar tissue distribution
in regions where ACKR3 is highly expressed.2,38,39 This
spatiotemporal regulation of PAMP-12 may follow a
mechanism similar to that described for CXCL12 and recently
for opioid peptides and should be the focus of future in vivo
investigations.40 Of note, even though Ackr3 knockout in mice
shows a similar phenotype as Adm overexpression, a recent
study revealed that ADMΔPAMP/ΔPAMP mice, which carry the
ADM but lack the PAMP-coding sequence, had no obvious
anomalies, pointing toward a more complex (possibly dual
ADM/PAMP-12) or non-homeostatic scavenging role of
ACKR3 in the regulation of these peptides.41 Finally, in
analogy to ACKR3 interplay with CXCR4 described to alter
the signaling properties of the latter,42−44 the ability of ACKR3
to heterodimerize with MrgX2 and/or CLR receptors and
modulate their activity remains to be investigated. Additionally,
the trafficking and signaling properties of the two receptors
may be indirectly affected by ACKR3’s interaction with
RAMP3 that was recently reported to regulate its cycling.13
In conclusion, our study identifies ACKR3 as the first dual
ADM/PAMP receptor and sheds light on the complex
regulation of the availability of proADM-derived peptides.
■ MATERIALS AND METHODS
Chemokines and Peptides. All chemokines were
purchased from PeproTech. AlexaFluor647-labeled CXCL12
(CXCL12−AF647) was obtained from Almac. ADM and all
other peptides from the CGRP family, as well as PAMP and
PAMP(12−20) were acquired from Bachem. PAMP-12 was
purchased from Phoenix Pharmaceuticals. PAMP-12 variants
and (5-FAM)-labeled PAMP were synthesized by JPT. These
peptides contain a free amine at the N-terminus and an amide
group at the C-terminus.
Cell Culture. HEK293T cells were purchased from ATCC
and grown in DMEM supplemented with 10% fetal bovine
serum (FBS) and penicillin/streptomycin (100 units/mL and
100 μg/mL). HEK293T cells stably expressing ACKR3 (HEK-
ACKR3) were generated by transfection with a pIRES vector
encoding human ACKR3 and maintained under puromycin (5
μg/mL) selective pressure. Cells were regularly tested for
mycoplasma contamination.
Binding Competition Assay. The assay was performed as
previously described.27,45 In brief, HEK-ACKR3 cells were
distributed into 96-well plates (2 × 105 cells/well) and
incubated with a mixture of CXCL12−AF647 (5 nM) and
unlabeled peptides at indicated concentrations in FACS buffer
(PBS, 1% BSA, 0.1% NaN3) for 90 min on ice. After two
washing steps, the cells were incubated for 30 min at 4 °C with
Zombie Green viability dye (BioLegend). After two washing
steps, the cells were resuspended in FACS buffer and mean
fluorescence intensity (MFI) was measured from 10 000 gated
cells using a BD LSR Fortessa flow cytometer. The signal
obtained for CXCL12−AF647 in the absence of unlabeled
ligands was defined as 100% binding, and signal for CXCL12−
AF647 in the presence of 1 μM unlabeled CXCL12 was set to
0%.
Nanoluciferase Complementation-Based Assay
(NanoBiT). Ligand-induced recruitment of β-arrestin, miniGi
or miniGq proteins (engineered GTPase domain of Gα
subunit)46,47 to the receptors was monitored using NanoBiT
technology (Promega), as previously described.27,48 HEK293T
cells (5 × 106 cells) were seeded in 10 cm dishes, and 24 h
later, the cells were cotransfected with pNBe plasmids
encoding the receptor C-terminally fused to SmBiT and β-
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arrestin, miniGi, or miniGq N-terminally fused to LgBiT. After
24 h, the cells were detached and incubated for 25 min at 37
°C with Nano-Glo Live Cell substrate diluted 200-fold,
distributed into white 96-well plates (1 × 105 cells/well),
and treated with the indicated concentrations of peptides.
Luminescence was recorded during 20 min with a Mithras
LB940 luminometer (Berthold Technologies). For the
concentration−response curves, the signal recorded with a
saturating concentration of full agonist for each receptor was
set as 100%. For receptor screening experiments, results were
expressed as fold vehicle, and an agonist chemokine (100 nM)
listed in the IUPHAR repository of chemokine receptor ligands
was included as a positive control for each receptor.
Nanoluciferase Bioluminescence Resonance Energy
Transfer (NanoBRET). Ligand-induced receptor−arrestin
delivery to endosomes was monitored by NanoBRET. In
brief, 5 × 106 HEK293T cells were seeded in 10 cm dishes, and
24 h later, the cells were cotransfected with plasmids encoding
ACKR3, β-arrestin-2 N-terminally tagged with nanoluciferase
and the FYVE domain of endofin, interacting with
phosphatidylinositol 3-phosphate (PI3P) in early endo-
somes,36,49 N-terminally tagged with mNeonGreen. After 24
h, the cells were detached and distributed into black 96-well
plates (1 × 105 cells/well) and treated with saturating
concentrations of ligands (3 μM for peptides or 300 nM for
chemokines). After 30 min of incubation at 37 °C,
coelenterazine H (10 μM) was added, and donor emission
(460 nm) and acceptor emission (535 nm) were immediately
measured on a Mithras LB940 plate reader (Berthold
Technologies).
For receptor dimerization experiments, HEK293T cells were
seeded in a 12-well plate (5 × 105 cells/well). After 24 h, the
cells were transfected with 5 ng of donor-encoding pNLF
vector (RAMP, CD8, ACKR3, or CXCR4 C-terminally tagged
with nanoluciferase) and increasing concentrations of accept-
or-encoding pNeonGreen vector (ACKR3, CXCR4, or CLR
C-terminally tagged with mNeonGreen). An empty pcDNA3.1
vector was added to the different transfection mixes in order to
maintain a constant total amount of DNA. At 24 h post-
transfection, the cells were detached and seeded in black 96-
well plates (1 × 105 cells/well). The signal of mNeonGreen
was first quantified (excitation, 485 nm; emission, 535 nm)
and used to determine the acceptor/donor ratio. After
coelenterazine H (10 μM) addition, donor emission (460
nm) and acceptor emission (535 nm) were immediately
measured on a Mithras LB940 plate reader (Berthold
Technologies). BRET ratios were plotted against the
determined acceptor/donor ratio, and the data were fitted
using a nonlinear regression equation for one site-specific
binding.
Inducible Nanoluciferase Reporter Gene Transcrip-
tion Assays. Activation of the MAPK/ERK signaling pathway
was evaluated using an SRE nanoluciferase reporter assay.
Activation of calcium-dependent signaling pathways was
evaluated using an NFAT-RE nanoluciferase reporter assay.
In brief, 6 × 106 HEK293T cells were seeded in 10 cm dishes,
and 24 h later, the cells were cotransfected with a pcDNA3.1
encoding either ACKR3 or MrgX2 and pNanoLuc/SRE or
pNanoLuc/NFAT-RE vectors (Promega) containing the
nanoluciferase gene downstream of an SRE or NFAT-RE.
After 24 h, the cells were detached and seeded in white 96-well
plates (1 × 105 cells/well). After 24 h, the medium was
replaced by phenol-free DMEM, and after 2 h incubation,
chemokines, peptides, or positive control (30 nM phorbol 12-
myristate 13-acetate (PMA) + 10% FBS with or without 1 μM
ionomycin for NFAT-RE and SRE, respectively) were added.
After 6 h (SRE) or 8 h (NFAT-RE), Nano-Glo Live Cell
substrate (Promega) was added, and the luminescence was
read during 20 min on a Mithras LB940 plate reader (Berthold
Technologies).
HTRF-Based Determination of ERK1/2 Phosphoryla-
tion. An HTRF-based phospho-ERK1/2 (extracellular signal
regulated kinases 1 and 2) assay was performed using the
phospho-ERK1/2 (Thr202/Tyr204) cellular kit (Cisbio
International). In brief, 6 × 106 HEK293T cells were seeded
in 10 cm dishes and transfected 24 h later with pcDNA3.1
plasmid encoding ACKR3 or MrgX2. At 24 h post-trans-
fection, the cells were detached and seeded in 96-well plates (1
× 105 cells/well). After 24 h, the cell culture medium was
replaced with phenol-free DMEM, and after 90 min of
incubation, the cells were stimulated with PAMP-12 (3 μM),
vehicle, or epidermal growth factor (EGF, 100 nM) as positive
control for the indicated time intervals. Supernatants were
replaced with the provided lysis buffer, and 45 min later, the
lysates were transferred to a white 384-well plate. After a 2 h of
incubation with pERK1/2-specific antibodies conjugated to
Eu3+-cryptate donor and d2 acceptor at the recommended
dilutions, the HTRF signal was measured on a Tecan GENios
pro plate reader equipped with a 340 nm excitation filter and
612 ± 10 nm (donor) and 670 ± 25 nm (acceptor) emission
filters.
Visualization of PAMP-12-FAM Uptake by Imaging
Flow Cytometry. HEK293T or HEK-ACKR3 cells were
harvested in Opti-MEM and distributed into 96-well plates (3
× 105 cells/well). After a 15 min of incubation at 37 °C with
CXCL10, CXCL12, or Opti-MEM only, FAM-labeled PAMP-
12 was added to a final concentration of 3 μM and incubated
for 45 min at 37 °C; then the cells were washed twice with
FACS buffer. For comparison of labeled PAMP-12 uptake by
ACKR3 or MrgX2, 6 × 106 HEK293T cells were seeded in 10
cm dishes and transfected 24 h later with 4 μg of pcDNA3.1
plasmid encoding ACKR3 or MrgX2. At 24 h post-trans-
fection, the cells were harvested and treated as described
above. Dead cells were excluded using Zombie NIR viability
dye (BioLegend). Images of 1 × 104 in-focus, living single cells
were acquired with an ImageStream Mark II imaging flow
cytometer (Amnis) equipped with an extended depth of field
(EDF) module and using 60× magnification. Samples were
analyzed using Ideas6.2 software. The number of spots per cell
was determined using a mask-based software wizard.
Data and Statistical Analysis. Concentration−response
curves were fitted to the four-parameter Hill equation using an
iterative, least-squares method (GraphPad Prism version
8.0.1). All curves were fitted to data points generated from
the mean of at least three independent experiments. Statistical
tests, i.e., ordinary one-way ANOVA and post hoc analysis
were performed with GraphPad Prism 8.0.1. The p-values are
indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001;
and ****, p < 0.0001.
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